Skip to main content

Signifor FDA Approval History

FDA Approved: Yes (First approved December 14, 2012)
Brand name: Signifor
Generic name: pasireotide
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cushing's Syndrome

Signifor (pasireotide) is a multireceptor targeting somatostatin analog for the treatment of patients with Cushing's disease.

Development timeline for Signifor

Dec 14, 2012Approval FDA Approves Signifor, a New Orphan Drug for Cushing’s Disease
Nov  7, 2012Novartis drug Signifor recommended by FDA advisory committee for approval to treat patients with Cushing's disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.